Brainsway Ltd ADR Dossier - Source-backed chat

Brainsway Ltd ADR

BWAYNASDAQ

SectorHealth Care

IndustryHealth Care Equipment

Beta (adjusted)0.39

Intrinsic Value $6.70median of 6 methods · middle span $5-$64based on filings through 30 Jun 2025

Market Price $12.60Price as of 1 Oct 2026

OvervaluedIntrinsic value is 47% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $507.2M

Enterprise Value $439.3M

Shares Outstanding 37.7M diluted

Moat Rating None

Next Earnings Date18 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

BrainsWay is successfully transitioning into a highly profitable, high-margin, recurring-revenue medical technology leader. Driven by its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform, the company is experiencing rapid market penetration in major depressive disorder (MDD), obsessive-compulsive disorder (OCD), and smoking addiction. With a strong balance sheet featuring zero debt, robust cash reserves, and expanding remaining performance obligations (RPO), BrainsWay is well-positioned to capture significant market share while maintaining strong operating leverage.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets3 analysts · as of 18 Aug 2026

Low · most bearish analyst$17.00

Mean target$17.67

High · most bullish analyst$18.00

Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$11.0015%

Regulatory delays in securing the PTSD clearance push commercialization into late 2027. Increased competition in the non-invasive neurostimulation market slows down new system placements, and a shift away from lease agreements back to direct sales reduces long-term revenue visibility.

Base CaseCentral scenario

$17.0060%

BrainsWay achieves its full-year 2026 revenue guidance of $66 million to $68 million (representing 27% to 30% YoY growth) and delivers on its projected operating income margin of 13% to 14%. System shipments continue at a steady pace of 110+ per quarter, supported by growing payer acceptance of nurse practitioner-administered therapy.

Bull CaseUpside scenario

$23.0025%

Accelerated adoption of the SWIFT™ accelerated Deep TMS protocol and rapid FDA clearance of the PTSD with MDD indication drive system shipments well above guidance. Enterprise accounts expand rapidly, pushing gross margins toward 78% and operating margins above 16% as recurring lease revenues compound.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong financial momentum with Q1 2026 revenue growing 35% YoY to $15.5 million and net income more than doubling to $2.3 million.
High-margin recurring revenue model with approximately 70% of recent customer engagements structured as multi-year lease agreements.
Robust balance sheet with $58.9 million in cash and cash equivalents as of March 31, 2026, and zero debt.
Expanding clinical utility and regulatory catalysts, including the upcoming FDA decision on Deep TMS for PTSD with MDD.

Key Investment Risks

Dependence on third-party payer reimbursement policies and clinical acceptance of nurse practitioner-administered TMS.
Intense competition from alternative neurostimulation technologies and traditional pharmaceutical treatments.
Execution risks associated with strategic minority-stake investments in clinical platforms.

Thesis Invalidation Triggers

A significant decline in quarterly system shipments or a contraction in the total installed base.
Failure to obtain FDA clearance for the PTSD with MDD indication by early 2027.
Material deterioration of gross margins below 70% due to pricing pressure or supply chain disruptions.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.